Ongoing treatment(s)-Hormonal therapy - Page 3 of 10 Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Hormonal therapy Posts on Medivizor

The effect of exercise on fatigue in men receiving hormone therapy for prostate cancer

Posted by on Aug 14, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine the long-term effects of different exercises on fatigue in men with prostate cancer who are receiving hormone therapy. The authors concluded that different exercises had different but comparable effects on reducing fatigue during hormone therapy. Some background Hormone therapy is a common treatment...

Read More

Is abemaciclib combined with fulvestrant effective in women with HR positive advanced breast cancer?

Posted by on Jul 15, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the effectiveness of the combination of fulvestrant (Faslodex) and abemaciclib to fulvestrant alone in patients with advanced breast cancer. This study concluded that the combination of fulvestrant and abemaciclib had improved outcomes for patients when compared to fulvestrant alone.  Some background...

Read More

Radium 223-dichloride as a treatment for castration resistant prostate cancer

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell This study investigated how effective and safe radium 223 dichloride treatment was in patients with castration resistant prostate cancer (CRPC). It was concluded that radium 223 dichloride increased overall survival, reduced symptomatic skeletal events risk and was safe.  Some background Treatment to decrease the male hormones,...

Read More

The use of circulating tumor cells in predicting survival in chemotherapy patients

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to investigate if circulating tumor cells (CTC) levels in the blood could be used to determine the outcome for metastatic castration resistant prostate cancer patients. This study concluded that CTC levels could be used to predict survival in these patients.  Some background Treatment for metastatic...

Read More

Incidence of ovarian function recovery in women over 40 with chemotherapy induced amenorrhea

Posted by on Mar 13, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated ovarian function recovery (OFR) after chemotherapy-induced amenorrhea (absence of menstruation) in women aged 40-49 after 2 years of aromatase inhibitor (AI) therapy. The study concluded that a large number of women with chemotherapy-induced amenorrhea recover ovarian function during AI therapy.  Some...

Read More

Comparing outcomes of radiation therapy and observation in patients over 80

Posted by on Jan 5, 2017 in Prostate cancer | 0 comments

In a nutshell This study examined different treatment options for elderly men with localized prostate cancer. Researchers reported that radiation therapy with or without hormone therapy was associated with a significant survival benefit when compared to observation alone. Some background Localized prostate cancer refers to cancer that is confined...

Read More

Secondary hormone therapies: Should abiraterone or enzalutamide be administered first?

Posted by on Dec 19, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined whether abiraterone (Zytiga) or enzalutamide (Xtandi) should be administered first in the treatment of metastatic castration-resistant prostate cancer. Authors report preliminary evidence for reduced disease progression when administering abiraterone before enzalutamide compared to the reverse sequence. A significant...

Read More

Is there a benefit of radiation to lymph node metastases during hormone therapy?

Posted by on Dec 12, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the benefit of radiation to limited sites of cancer spread (metastases) in men no longer responding to hormone therapy. Researchers reported effective local cancer control after radiation of lymph node metastases in patients no longer responding to hormone therapy.  Some background Hormone therapy is the...

Read More